Project Grant R43FD006939

This $312,371 Project Grant award from the National Heart Lung and Blood Institute (CFDA #93.837 Cardiovascular Diseases Research) to Biochip Labs Inc., a small business based in Cleveland, Ohio, aims to support the manufacturing and analytical validation of the Microfluidic Impedance Red Cell Assay (MIRCA) for commercial viability. The MIRCA is an in vitro diagnostic technology that measures cellular obstruction in microcapillary networks due to abnormal red blood cell (RBC) deformability...

This Project Grant award of $234,000.00 was provided by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to the University of Colorado-Denver to develop "hemostatic red blood cells" (T-RBCs) that can bind to collagen and fibrin to enhance clot formation and stability. The goal is to create a novel technology to address severe, non-compressible bleeding, which is a major cause of mortality worldwide, especially in low-resource settings. The...

The National Heart, Lung, and Blood Institute (NHLBI) awarded a $297,587 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to General Fluidics Corporation to validate the performance of the AXESS system, a novel point-of-need clinical chemistry and hematology platform. The goal is to demonstrate equivalence between the AXESS system's results and those obtained from standard venous blood testing for a basic metabolic panel and complete blood count, using matched capillary and...

This Project Grant award of $2,461,670.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports the development of ErythroMer (EM), a dried, bio-inspired artificial red blood cell substitute, by Kalocyte Inc., a biotech startup. The project aims to optimize the lyophilization and reconstitution of EM to improve its oxygen binding and release properties, as well as evaluate its efficacy, pharmacokinetics, dosing, and compatibility with...

This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Texas Tech University System provides $587,878 to develop novel additive-manufactured devices for label-free magnetophoresis to fractionate red blood cells (RBCs). The research aims to separate healthy, hemoglobin-enriched RBCs from damaged or iron-deficient cells to extend the shelf life of RBC units and enable transfusion therapies that can alleviate negative effects...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $295,895 to Ricovr Healthcare Inc. to develop a rapid, low-cost, point-of-care (POC) diagnostic platform for quantitative measurement of placental growth factor (PlGF) to predict and detect pre-eclampsia. The goal is to create an objective, affordable POC tool to improve the clinical diagnosis and monitoring of pre-eclampsia, which...

This $200,000 Project Grant awarded by the National Science Foundation (NSF) Division of Electrical, Communications and Cyber Systems under CFDA 47.041 (Engineering) aims to develop and implement a novel testing platform to evaluate the accuracy of wearable photoplethysmography-based blood pressure monitoring devices. The University of Maryland, College Park will construct a bench flow phantom that simulates physiologically relevant blood pressure, blood flow, anatomical, and optical...

This federal Project Grant award of $110,635.00 from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to characterize how red blood cell aggregation and membrane deformability affect endothelial cell injury and microvascular thrombosis in sepsis patients. The project will use microfluidics assays to analyze patient blood samples and apply machine learning to determine the impact of rheology on clinical outcomes. The research will also assess the...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) is funding the development of a "Fail Safe, High Output Failing Fontan Pump" to provide mechanical circulatory support for individuals with congenital heart disease and single ventricle physiology. The $320,838 award to Perfusion Solutions Inc. (UEI: TF8CUC65VLG5) supports the hydraulic design refinement and component development of a...

This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) is providing $1,031,644 to support research on precision metering and autonomous separation of blood components for pre-clinical microsampling at the point-of-care. The primary awardee, Trustees of Tufts College, will develop functional patient-centric devices that can stabilize...